zurück

Tebentafusp (new indication: uveal melanoma HLA-A*02:01-positive adult patients)


Subject:

  • Active Substance: Tebentafusp
  • Name: Kimmtrak®
  • Therapeutic area: Melanoma
  • Pharmaceutical company: Immunocore Ireland Ltd.


Time table:

  • Start: 01.05.2022
  • Final decision by G-BA: 20.10.2022


Final decision:

  • No additional benefit proved